Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.69 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | KDM1A | O60341 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.53 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.51 |
| ▸ | VNN1 | O95497 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.50 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.49 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27822779 | 0.83 | L3MBTL1 (0.81) | L3MBTL1EPHX2CACNA1BAPBA1NPC1 | |
| SCHEMBL28443041 | 0.82 | L3MBTL1 (0.74) | L3MBTL1EPHX2HDAC1CACNA1BAPBA1 | |
| SCHEMBL5083105 | 0.82 | L3MBTL1 (0.74) | L3MBTL1EPHX2CACNA1BAPBA1NPC1 | |
| SCHEMBL16109524 | 0.82 | EPHX2 (0.56) | L3MBTL1EPHX2KDM1AHDAC1EGLN1 | |
| SCHEMBL4067449 | 0.82 | L3MBTL1 (1.00) | L3MBTL1EPHX2CACNA1BAPBA1NPC1 | |
| SCHEMBL28049871 | 0.81 | L3MBTL1 (0.72) | L3MBTL1HDAC1CACNA1BAPBA1RAB9A | |
| SCHEMBL31023556 | 0.80 | L3MBTL1 (0.84) | L3MBTL1EPHX2HDAC1CACNA1BAPBA1 | |
| SCHEMBL3162987 | 0.79 | L3MBTL1 (0.69) | L3MBTL1EPHX2KDM1AHDAC1CACNA1B | |
| SCHEMBL3098294 | 0.79 | MEN1 (0.77) | L3MBTL1EPHX2KDM1AHDAC1CACNA1B | |
| SCHEMBL10645032 | 0.77 | L3MBTL1 (0.58) | L3MBTL1CACNA1BAPBA1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407409-B2 | 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20180186772-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | TAKEDA CALIFORNIA, INC. | 2018-07-05 | — | — | US | disclosed |
| EP-3336084-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE DERIVATIVES AND THEIR USE AS PHD INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2018-06-20 | — | — | EP | disclosed |
| US-9944626-B2 | 6-(5-hydroxy-1H-pyrazol-1-YL)nicotinamide inhibitors of PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-04-17 | — | — | US | disclosed |
| US-20170275271-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | TAKEDA CALIFORNIA, INC. | 2017-09-28 | — | — | US | disclosed |
| US-9708296-B2 | 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-07-18 | — | — | US | disclosed |
| US-20160251337-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9345713-B2 | 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-24 | — | — | US | disclosed |
| EP-2978752-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE DERIVATIVES AND THEIR USE AS PHD INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2016-02-03 | — | — | EP | disclosed |
| US-20150224113-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2015-08-13 | — | — | US | disclosed |
| US-9040522-B2 | 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-26 | — | — | US | disclosed |
| WO-2014160810-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE DERIVATIVES AND THEIR USE AS PHD INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-10-02 | — | — | WO | disclosed |
| US-20140296200-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224113-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | SIRT1, SIRT3, SIRT5 | L3MBTL1 4186/4885EPHX2 2496/4885KDM1A 208/4885 |
| US-20180186772-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | HIF1AN, EGLN3, EGLN2 | L3MBTL1 4653/4885EPHX2 1337/4885KDM1A 79/4885 |
| US-20170275271-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | HIF1AN, EGLN3, EGLN2 | L3MBTL1 4653/4885EPHX2 1337/4885KDM1A 79/4885 |
| US-20140296200-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | HIF1AN, EGLN3, EGLN2 | L3MBTL1 4653/4885EPHX2 1337/4885KDM1A 79/4885 |
| US-10407409-B2 | 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD | HIF1AN, EGLN3, EGLN2 | L3MBTL1 4653/4885EPHX2 1337/4885KDM1A 79/4885 |
| US-20160251337-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | HIF1AN, EGLN3, EGLN2 | L3MBTL1 4653/4885EPHX2 1337/4885KDM1A 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.